Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 535-542

  Brüning, Ansgar ^a,b   Burger, Petra ^a   Vogel, Marianne ^a   Gingelmaier, Andrea ^a   Friese, Klaus ^a   Burges, Alexander ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apoptosis; Mcl 1; Mitochondria; Nelfinavir; Ovarian cancer; Sorafenib

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NELFINAVIR; PROTEIN MCL 1; SERINE; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID LEUKEMIA FACTOR 1; NICOTINAMIDE; PROPIDIUM IODIDE; PROTEIN BCL 2; PYRIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL PROTECTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; UPREGULATION; ANALOGS AND DERIVATIVES; CELL DEATH; DRUG EFFECTS; DRUG POTENTIATION; ENZYMOLOGY; METABOLISM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; NELFINAVIR; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROPIDIUM; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIDINES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77956058105     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9281-1     Document Type: Article

References (35)

1. N Pore AK Gupta GJ Cerniglia A Maity 2006 HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells Neoplasia 8 889 895 10.1593/neo.06535 1:CAS:528:DC%2BD28Xht1eitrfO 17132220
2. JJ Gills J Lopiccolo J Tsurutani RH Shoemaker CJ Best MS Abu-Asab J Borojerdi NA Warfel ER Gardner M Danish MC Hollander S Kawabata M Tsokos WD Figg PS Steeg PA Dennis 2007 Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo Clin Cancer Res 13 5183 5194 10.1158/1078-0432.CCR-07-0161 1:CAS:528:DC%2BD2sXpvFGqs7o%3D 17785575
3. J Cohen 2007 Biomedicine. HIV drug shows promise as potential cancer treatment Science 317 1305 10.1126/science.317.5843.1305 1:CAS:528: DC%2BD2sXhtVeksrvM 17823319
4. JP Plastaras N Vapiwala MS Ahmed D Gudonis GJ Cerniglia MD Feldman I Frank AK Gupta 2008 Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans Cancer Biol Ther 7 628 635 1:CAS:528:DC%2BD1cXhtVeisLvJ 18285707
5. TB Brunner M Geiger GG Grabenbauer M Lang-Welzenbach TS Mantoni A Cavallaro R Sauer W Hohenberger WG McKenna 2008 Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer J Clin Oncol 26 2699 2706 10.1200/JCO.2007.15.2355 1:CAS:528:DC%2BD1cXnvVOhsbw%3D 18509182
6. WA Chow C Jiang M Guan 2009 Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10 61 71 10.1016/S1470-2045(08)70334-6 1:CAS:528:DC%2BD1cXhsFChtbnP 19111246
7. A Brüning M Vogel P Burger M Rahmeh A Gingelmaier K Friese M Lenhard A Burges 2008 Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells Biochem Biophys Res Commun 377 1309 1314 10.1016/j.bbrc.2008.10.167 19000651
8. A Brüning P Burger M Vogel M Rahmeh A Gingelmaier K Friese M Lenhard A Burges 2008 Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis Cancer Biol Ther 8 226 232
9. SR Vlahakis SA Bennett SN Whitehead AD Badley 2007 HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo Apoptosis 12 969 977 10.1007/s10495-007-0755-3 1:CAS:528:DC%2BD2sXksFamsLc%3D 17453162
10. SA Rizza AD Badley 2008 HIV protease inhibitors impact on apoptosis Med Chem 4 75 79 10.2174/157340608783331443 1:CAS:528:DC%2BD1cXhsV2ktLg%3D 18220972
11. T Hisatomi T Nakazawa K Noda L Almulki S Miyahara S Nakao Y Ito H She R Kohno N Michaud T Ishibashi A Hafezi-Moghadam AD Badley G Kroemer JW Miller 2008 HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice J Clin Invest 118 2025 2038 1:CAS:528: DC%2BD1cXntVCmt78%3D 18497877
12. S Fulda 2008 Targeting inhibitor of apoptosis proteins (IAPs) for cancer therapy Anticancer Agents Med Chem 8 533 539 1:CAS:528:DC%2BD1cXmvVarsro%3D 18537535
13. JK Brunelle A Letai 2009 Control of mitochondrial apoptosis by the Bcl-2 family J Cell Sci 122 437 441 10.1242/jcs.031682 1:CAS:528:DC%2BD1MXjs1Wls7w%3D 19193868
14. KW Yip JC Reed 2008 Bcl-2 family proteins and cancer Oncogene 27 6398 6406 10.1038/onc.2008.307 1:CAS:528:DC%2BD1cXht12ltLvO 18955968
15. MR Warr GC Shore 2008 Unique biology of Mcl-1: therapeutic opportunities in cancer Curr Mol Med 8 138 147 10.2174/156652408783769580 1:CAS:528: DC%2BD1cXktlWgsLc%3D 18336294
16. C Weng Y Li D Xu Y Shi H Tang 2005 Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells J Biol Chem 280 10491 10500 10.1074/jbc.M412819200 1:CAS:528:DC%2BD2MXit1ersLw%3D 15637055
17. JT Opferman 2006 Unraveling MCL-1 degradation Cell Death Differ 13 1260 1262 10.1038/sj.cdd.4401978 1:CAS:528:DC%2BD28XmvFaitb8%3D 16710358
18. AM Domina JA Vrana MA Gregory SR Hann RW Craig 2004 MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol Oncogene 23 5301 5315 10.1038/sj.onc.1207692 1:CAS:528:DC%2BD2cXlsVOmsLo%3D 15241487
19. S Kobayashi SH Lee XW Meng JL Mott SF Bronk NW Werneburg RW Craig SH Kaufmann GJ Gores 2007 Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1 J Biol Chem 282 18407 18417 10.1074/jbc.M610010200 1:CAS:528:DC%2BD2sXmsVOks78%3D 17463001
20. R Mohammad A Giri AS Goustin 2008 Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer Recent Pat Anticancer Drug Discov 3 20 30 10.2174/157489208783478676 1:CAS:528:DC%2BD1cXjs1agtL8%3D 18289121
21. M Vogler D Dinsdale MJ Dyer GM Cohen 2009 Bcl-2 inhibitors: small molecules with a big impact on cancer therapy Cell Death Differ 16 360 367 10.1038/cdd.2008.137 1:CAS:528:DC%2BD1MXit1WkurY%3D 18806758
22. C Akgul 2009 Mcl-1 is a potential therapeutic target in multiple types of cancer Cell Mol Life Sci 66 1326 1336 10.1007/s00018-008-8637-6 1:CAS:528:DC%2BD1MXksFGhtb4%3D 19099185
23. P Ulivi C Arienti D Amadori F Fabbri S Carloni A Tesei I Vannini R Silvestrini W Zoli 2009 Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines J Cell Physiol 220 214 221 10.1002/jcp.21753 1:CAS:528:DC%2BD1MXmvVGitbs%3D 19288493
24. A Mastrolorenzo S Rusconi A Scozzafava G Barbaro CT Supuran 2007 Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors Curr Med Chem 14 2734 2748 10.2174/092986707782360141 1:CAS:528:DC%2BD1cXhtlSkurc%3D 18045120
25. H Schulze-Bergkamen B Fleischer M Schuchmann A Weber A Weinmann PH Krammer PR Galle 2006 Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction BMC Cancer 6 232 10.1186/1471-2407-6-232 17014711
26. KW Adams GM Cooper 2007 Rapid turnover of mcl-1 couples translation to cell survival and apoptosis J Biol Chem 282 6192 6200 10.1074/jbc.M610643200 1:CAS:528:DC%2BD2sXitVCisr4%3D 17200126
27. N Chetoui K Sylla JV Gagnon-Houde C Alcaide-Loridan D Charron R Al-Daccak F Aoudjit 2008 Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis Mol Cancer Res 6 42 52 10.1158/1541-7786.MCR-07-0080 1:CAS:528:DC%2BD1cXhtFyisbc%3D 18234961
28. SH Wei K Dong F Lin X Wang B Li JJ Shen Q Zhang R Wang HZ Zhang 2008 Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell Cancer Chemother Pharmacol 62 1055 1064 10.1007/s00280-008-0697-7 1:CAS:528:DC%2BD1cXhtFaju7%2FI 18297287
29. BK Vakkalanka RM Bukowski 2008 Novel drugs for renal cell carcinoma Expert Opin Investig Drugs 17 1501 1516 10.1517/13543784.17.10.1501 1:CAS:528:DC%2BD1cXhtFCjur3J 18808310
30. TE Hutson RA Figlin 2008 Experimental therapy for advanced renal cell carcinoma Expert Opin Investig Drugs 17 1693 1702 10.1517/13543784.17.11.1693 1:CAS:528:DC%2BD1cXht1CmsbnJ 18922106
31. GM Keating A Santoro 2009 Sorafenib: a review of its use in advanced hepatocellular carcinoma Drugs 69 223 240 10.2165/00003495-200969020-00006 1:CAS:528:DC%2BD1MXkvFClsb8%3D 19228077
32. R Ng EX Chen 2006 Sorafenib (BAY 43-9006): review of clinical development Curr Clin Pharmacol 1 223 228 10.2174/157488406778249325 1:CAS:528: DC%2BD28XpvFOnsLs%3D 18666747
33. L Dal Lago V D'Hondt A Awada 2008 Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors Oncologist 13 8 845 858 10.1634/theoncologist.2007-0233 1:CAS:528: DC%2BD1cXhtF2qs7vJ 18695262
34. C Sgadari P Monini G Barillari B Ensoli 2003 Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth Lancet Oncol 4 537 547 10.1016/S1470-2045(03)01192-6 1:CAS:528:DC%2BD3sXntVGhsrw%3D 12965274
35. Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B, Wegner S (2009) The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 50 (ahead of print) doi: 10.1097/QAI.0b013e3181aa13c7